注射用单磷酸阿糖腺苷专项处方点评干预的成效分析 : = Analysis on Effectiveness of Special Prescription Comment on Vidarabine Monophosphate for Injection
目的:分析并建立注射用单磷酸阿糖腺苷专项处方点评模式,加强处方合理使用点评与管理,为临床儿童安全、合理用药提供参考。方法:抽取2016年6月份医院门诊所有含注射用单磷酸阿糖腺苷的门诊处方,按照《处方管理办法》、《医院处方点评管理规范(试行)》的要求由药师对处方进行初步的分析点评,将点评结果提交医院处方点评专家组讨论,最后点评结果由点评专家组交由医务处进行公示;另抽取2016年10月按照相同标准点评专项处方进行效果确认。结果:经过专项处方点评公示配合医院行政处理4月后,注射用单磷酸阿糖腺苷的单药处方数由整治前的546张降为整治后的230张,单磷酸阿糖腺苷使用合格率由整治前的1.10%提高至整治后的24.34%,该药使用合理性得到明显改善。结论:基于处方专家组的专项处方点评模式结合行政奖惩制度的有效落实,提高了医院的处方合格率,但目前仍然着眼于事后点评,仍需进一步健全医院信息化建设,加强处方前置审核的地位,以确保患者用药的安全性和有效性。.
Objective:To analyze and establish a prescription evaluation model of vidarabine monophosphate, to strengthen the management of rational use, and to provide a reference for safe and rational drug use in clinical children.Methods:A total sample of outpatient prescriptions containing vidarabine monophosphate were selected from June to October 2016. According to the requirements of "Prescription Management Measures" and "Hospital Prescription Review Management Standards"(trial implementation), pharmacists made a retrospective review of the prescriptions and submitted the results to the Hospital Prescription Review Expert Group. After discussion, the final result will be handed over to the Medical Department for publicity and punishment. Results:After 4 months of prescription evaluation and public announcement combined with hospital administrative treatment, the number of single prescription of vidarabine monophosphate decreased from 546 before treatment to 230 after treatment, and the qualified rate of vidarabine monophosphate prescription use increased from 1.10% before treatment to 24.34% after treatment. The rationality of the drug use was improved significantly. Conclusion:The special prescription evaluation model based on expert group and the effective reward and punishment system improved the prescription rational rate, but at present we still had to focus on post-comment. It is necessary to improve the hospital informatization and focus on the pre-prescription auditing so as to ensure the safety and effectiveness of the patient medication..
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2019-11-25 2019 |
|---|---|
| Erschienen: |
2019-11-25 |
| Enthalten in: |
Zur Gesamtaufnahme - year:2019 |
|---|---|
| Enthalten in: |
Kang gan ran yao xue - (2019), 11 vom: 25. Nov., Seite 1863-1866 Original Letters: Enthalten in 抗感染药学 (DE-600)2993606-8 (DE-600)2993606-8 江苏省苏州市 |
| Reihe: |
China Academic Journals (CAJ), E, 医药卫生科技 = Medicine & Public Health |
|---|
| Sprache: |
Chinesisch |
|---|
| Weiterer Titel: |
Analysis on Effectiveness of Special Prescription Comment on Vidarabine Monophosphate for Injection |
|---|
| Beteiligte Personen: |
|---|
| Links: |
oversea.cnki.net [lizenzpflichtig] |
|---|
| Themen: |
专项处方点评 |
|---|
| Anmerkungen: |
Author info:ZHONG Wen;HUANG Yan;ZHOU Feng;Children's Hospital Affiliated to Suzhou University;Suzhou No.5 People's Hospital |
|---|
| Förderinstitution / Projekttitel: |
|
|---|
| PPN (Katalog-ID): |
CAJ647386763 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | CAJ647386763 | ||
| 003 | DE-627 | ||
| 005 | 20230121131903.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 230104s2019 cc |||||o 00| ||chi c | ||
| 035 | |a (DE-627)CAJ647386763 | ||
| 035 | |a (SBB-XA)CAJ_KGYY201911010 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a chi | ||
| 044 | |c XB-CN | ||
| 084 | |a ASIEN |q DE-1a |2 fid | ||
| 084 | |a R95 |2 clc | ||
| 100 | 0 | |a 钟文 |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a 注射用单磷酸阿糖腺苷专项处方点评干预的成效分析 |b = Analysis on Effectiveness of Special Prescription Comment on Vidarabine Monophosphate for Injection |
| 246 | 3 | 1 | |a Analysis on Effectiveness of Special Prescription Comment on Vidarabine Monophosphate for Injection |
| 264 | 1 | |c 2019-11-25 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 490 | 0 | |a China Academic Journals (CAJ) |a E |a 医药卫生科技 = Medicine & Public Health | |
| 500 | |a Author info:ZHONG Wen;HUANG Yan;ZHOU Feng;Children's Hospital Affiliated to Suzhou University;Suzhou No.5 People's Hospital | ||
| 520 | |a 目的:分析并建立注射用单磷酸阿糖腺苷专项处方点评模式,加强处方合理使用点评与管理,为临床儿童安全、合理用药提供参考。方法:抽取2016年6月份医院门诊所有含注射用单磷酸阿糖腺苷的门诊处方,按照《处方管理办法》、《医院处方点评管理规范(试行)》的要求由药师对处方进行初步的分析点评,将点评结果提交医院处方点评专家组讨论,最后点评结果由点评专家组交由医务处进行公示;另抽取2016年10月按照相同标准点评专项处方进行效果确认。结果:经过专项处方点评公示配合医院行政处理4月后,注射用单磷酸阿糖腺苷的单药处方数由整治前的546张降为整治后的230张,单磷酸阿糖腺苷使用合格率由整治前的1.10%提高至整治后的24.34%,该药使用合理性得到明显改善。结论:基于处方专家组的专项处方点评模式结合行政奖惩制度的有效落实,提高了医院的处方合格率,但目前仍然着眼于事后点评,仍需进一步健全医院信息化建设,加强处方前置审核的地位,以确保患者用药的安全性和有效性。 | ||
| 520 | |a Objective:To analyze and establish a prescription evaluation model of vidarabine monophosphate, to strengthen the management of rational use, and to provide a reference for safe and rational drug use in clinical children.Methods:A total sample of outpatient prescriptions containing vidarabine monophosphate were selected from June to October 2016. According to the requirements of "Prescription Management Measures" and "Hospital Prescription Review Management Standards"(trial implementation), pharmacists made a retrospective review of the prescriptions and submitted the results to the Hospital Prescription Review Expert Group. After discussion, the final result will be handed over to the Medical Department for publicity and punishment. Results:After 4 months of prescription evaluation and public announcement combined with hospital administrative treatment, the number of single prescription of vidarabine monophosphate decreased from 546 before treatment to 230 after treatment, and the qualified rate of vidarabine monophosphate prescription use increased from 1.10% before treatment to 24.34% after treatment. The rationality of the drug use was improved significantly. Conclusion:The special prescription evaluation model based on expert group and the effective reward and punishment system improved the prescription rational rate, but at present we still had to focus on post-comment. It is necessary to improve the hospital informatization and focus on the pre-prescription auditing so as to ensure the safety and effectiveness of the patient medication. | ||
| 610 | 2 | 4 | |a 苏州大学附属儿童医院 |
| 610 | 2 | 4 | |a 苏州市第五人民医院 |
| 650 | 4 | |a 药事组织 | |
| 650 | 4 | |a 药学 | |
| 650 | 4 | |a 医药、卫生 | |
| 650 | 4 | |a Pharmaceutics | |
| 650 | 4 | |a 医药卫生科技 | |
| 650 | 4 | |a Medicine & Public Health | |
| 650 | 4 | |a 注射用单磷酸阿糖腺苷 | |
| 650 | 4 | |a 专项处方点评 | |
| 650 | 4 | |a 合理用药 | |
| 650 | 4 | |a 成效分析 | |
| 650 | 4 | |a vidarabine monophosphate | |
| 650 | 4 | |a special prescription comment | |
| 650 | 4 | |a rational use of drugs | |
| 650 | 4 | |a results analysis | |
| 700 | 0 | |a 黄艳 |4 oth | |
| 700 | 0 | |a 周峰 |4 oth | |
| 773 | 0 | 8 | |6 880-01 |i Enthalten in |t Kang gan ran yao xue |d Jiang su sheng su zhou shi, 1997 |g (2019), 11 vom: 25. Nov., Seite 1863-1866 |h Online-Ressource |w (DE-627)CAJ173494803 |w (DE-600)2993606-8 |7 nnns |
| 773 | 1 | 8 | |g year:2019 |g number:11 |g day:25 |g month:11 |g pages:1863-1866 |
| 856 | 4 | 0 | |u http://erf.sbb.spk-berlin.de/han/caj/oversea.cnki.net/kcms/detail/detail.aspx?dbcode=CJFD&filename=KGYY201911010 |x Verlag |y CrossAsia Link |z Deutschlandweit zugänglich |
| 856 | 4 | 0 | |u https://oversea.cnki.net/kcms/detail/detail.aspx?dbcode=CJFD&filename=KGYY201911010 |x Verlag |z lizenzpflichtig |
| 880 | 0 | 8 | |6 773-01/Hans |i Enthalten in |t 抗感染药学 |d 江苏省苏州市 |h Online-Ressource |w (DE-627)CAJ173494803 |w (DE-600)2993606-8 |7 nnns |
| 912 | |a ZDB-1-CAJ | ||
| 912 | |a GBV_NL_CAJ | ||
| 912 | |a FID-ASIEN | ||
| 912 | |a SSG-OLC-OA3.1 | ||
| 912 | |a SSG-OLC-CAJ | ||
| 936 | u | w | |j 2019 |e 11 |b 25 |c 11 |h 1863-1866 |
| 951 | |a AR | ||
| 952 | |j 2019 |e 11 |b 25 |c 11 |h 1863-1866 | ||
| 980 | |2 11 |1 01 |x 0001 |b 666891435 |c 00 |f 5:FIDXASIA |d --%%-- |e --%%-- |j --%%-- |y k |z 04-01-23 | ||
| 981 | |2 11 |1 01 |x 0001 |r http://erf.sbb.spk-berlin.de/han/caj/oversea.cnki.net/kcms/detail/detail.aspx?dbcode=CJFD&filename=KGYY201911010 | ||